INS and metabolic syndrome: In 2019, Zhang et al. conducted the first systematic review investigating the impact of Allo-FMT in obesity and metabolic syndrome, and concluded that the procedure was associated with short-term improvements in insulin sensitivity, but had no effect on any other cardiometabolic risk markers including weight loss [117].